2024 Gathering

4th Annual End Lung Cancer Now Gathering

ADVOCATES AMPLIFY RESEARCH. RESEARCH CURES CANCER.

Advances in lung cancer treatment come only from clinical trials, but less than 5% of eligible patients currently participate.

This year’s 4th Annual End Lung Cancer Gathering will serve to educate and empower advocates on the critical importance of research to advance treatments and improve outcomes for those impacted by lung cancer.

Event Highlights

Learn from the experts: Gain comprehensive knowledge from national experts how you, as a lung cancer advocate, can play a role in advancing research efforts statewide.
Interactivebreakout sessions: Engage in hands-on breakout sessions and collaborate with fellow attendees to develop a comprehensive research toolkit. This toolkit aims to promote research participation by addressing the challenges and barriers across the entire continuum of lung cancer care.
Networking opportunities: Connect with researchers, healthcare professionals, and fellow advocates to share experiences and strategies.

Why Attend?

Empowerment: Equip yourself with the knowledge and tools needed to make a significant impact in the fight against lung cancer.
Collaboration: Work alongside experts and fellow advocates to create solutions that drive research forward.
Advocacy: Learn how to effectively advocate for increased research funding and support within your community and beyond.

Who Should Attend?

Lung cancer patients and survivors
Caregivers and family members
Healthcare professionals
Researchers and scientists
Advocacy groups and non-profit organizations

Don’t miss this opportunity to be a part of a movement that is making a real difference in lung cancer research. Together, we can overcome the challenges and pave the way for better treatments and outcomes. Together, we can end lung cancer now.

Program Agenda
Time	Activity
8 a.m.	Welcome & End Lung Cancer Now Year in Review MacKenzie Church, End Lung Cancer Now
8:20 a.m.	Current State of Lung Cancer Nasser Hanna, MD
8:30 a.m.	Lung Cancer Research: A Patient’s Perspective Jill Feldman Co-founder, EGFR Resisters 2024 ASCO Patient Advocate Award Recipient
8:50 a.m.	Behind the Scenes with a Lung Cancer Researcher Eric Singhi, MD Assistant Professor, Department of General Oncology MD Anderson Cancer Center
9:10 a.m.	Implementation of Clinical Trials Brian Stemme CEO, Hoosier Cancer Research Network
9:30 a.m.	Focus Group Overview MacKenzie Church, End Lung Cancer Now
9:40 a.m.	Break / Exhibits & Vendors
10 a.m.	Focus Groups: Refining the Research Toolkit
11:35 a.m.	Break / Exhibits & Vendors
12 p.m.	Lunch
12:30 p.m.	Lung Cancer Survivor Story
12:50 p.m.	Adjourn / Exhibits & Vendors

Featured Speakers

Jill Feldman

Lung Cancer Patient and Advocate
Co-Founder EGFR Resisters

Jill Feldman is a lung cancer patient and advocate. With an extensive family history of lung cancer, Jill got involved in lung cancer advocacy in 2001, when it was in its infancy. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR-positive lung cancer.

Jill is committed to understanding and promoting patient-centered research as past chair of the International Association for the Study of Lung Cancer’s patient advisory board, a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a member of the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee, and as the patient advocate on the National Lung Cancer Round Table steering committee. In addition, she is a co-founder of the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will pro-long and better the lives of people diagnosed with EGFRm-positive lung cancer.

Jill serves in various other leadership roles to improve the speed and quality of research and use her voice and privilege to embed a health equity lens in all aspects of research and care. She is passionate about advocating for the critical aspects of the lived experience, including the physical, psychosocial, logistical, and financial effects of cancer and treatment on patients and families.

Eric Singhi, MD

Assistant Professor, Department of General Oncology
MD Anderson Cancer Center

Dr. Eric K. Singhi is an assistant professor and thoracic medical oncologist at the University of Texas MD Anderson Cancer Center. He completed his internal medicine residency at Vanderbilt University and served as chief hematology/oncology fellow at MD Anderson during his training. Dr. Singhi specializes in patient education research, and the care and research of young patients with lung cancer. Additionally, within MD Anderson Cancer Center, he serves as the patient safety and quality officer for the Thoracic/Head and Neck Medical Oncology Department, and as co-director of the thoracic medical oncology rotation for the medical oncology fellowship program.

Brian Stemme

Chief Executive Officer, Hoosier Cancer Research Network

Brian Stemme is the CEO of Hoosier Cancer Research Network Inc., (HCRN), a nonprofit organization that advances clinical research by collaborating with academic institutions, community hospitals, pharmaceutical companies, and cancer-focused nonprofits to bring new treatments to patients. HCRN manages 90 clinical trials and supports multiple research collaborations, including the Big Ten Cancer Research Consortium. He oversees a team of 60 professionals.

Prior to HCRN, Stemme was a senior vice president at BioCrossroads and manager at Eli Lilly and Company. He is a member of the Butler University Board of Trustees, his undergraduate alma mater.